Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results

Medical Xpress - latest medical and health news stories · 1h ago

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter,…

Read original article on Medical Xpress - latest medical and health news stories →

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results

Related news